Expression of VEGF-C/VEGFR-3 in human laryngeal squamous cell carcinomas and its significance for lymphatic metastasis

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 1, 2012, Pages 27-31

  Wang, Zhongliang ^a   Chen, Yao ^b   Li, Xiaofeng ^a   Xu, Li ^a   Ma, Wei ^a   Chang, Lingmei ^a   Ju, Funian ^a  

^a NORTHERN JIANGSU PEOPLE S HOSPITAL   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Laryngeal squamous cell carcinomas; Lymph node metastasis; VEGF C; VEGFR 3

Indexed keywords

MESSENGER RNA; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 3; VEGFC PROTEIN, HUMAN;

AGED; ARTICLE; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; FEMALE; GENETICS; HUMAN; LARYNX; LARYNX TUMOR; LYMPH NODE METASTASIS; MALE; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA;

AGED; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LARYNGEAL NEOPLASMS; LARYNX; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84864866638     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.1.027     Document Type: Article

References (20)

1. Eriksson U, Alitalo K (1999). Structure expression and receptor-binding properties of novel vascular endothelial growth factors. In: Claesson-Welsb L, editor. Vascular Growth Factors and Angiogenesis. Berlin Springer-Verlag
2. Fellmer PT, Sato K, Tanaka R, et al (1999). Vascular endothelial growth factor-C gene expression in papillary and follicular thyroid carcinomas. Surgery, 126, 1056.
3. Jeltsch M, Kaipainen A, Joukov V, et al (1997). Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science, 276, 1423-5.
4. Joukov V, Pajusola K, Kaipainen A, et al (1996). A new vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. Embo J, 15, 290.
5. Kaipainen A, Korhonen J, Mustonen T, et al (1995). Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA, 92, 3566-70.
6. Kowalski LP, Medina JE (1998). Nodal metastases: predictive factors. Otolaryngol Clin North Am, 31, 621-37.
7. Kukk E, Lymboussaki A, Taira S, et al (1996). VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development, 122, 3829-37.
8. Mork J (1998). Forty years of monitoring head and neck cancer in Norway--no good news. Anticancer Res, 18, 3705-8.
9. Ogawa S, Oku A, Sawano A, et al (1998). A novel type of vascular endothelial factor, VEGF-E (NA-7 VEGF), preferentially utilizes KDR/Flt-1 receptor and carries apotent mitotic activity without beparin-binding domain. J Biol Chem, 273, 31273.
10. Oh SJ, Jeltsch MM, Birkenhager R, et al (1997). VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev Biol, 188, 96-109.
11. Pajusola K, Aprelikova O, Korhonen J, et al (1992). FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines. Cancer Res, 52, 5738-43.
12. Salven P, Lymboussaki A, Heikkila P, et al (1998). Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human cancers. Am J Pathol, 153, 103- 8.
13. Shushanov S, Bronstein M, Adelaide J (2000). VEGFc and VEGFR3 expression in human thyroid pathologies. Int j cancer, 86, 47.
14. Sobin LH, Wittekind Ch (1997). UICC TNM classification of malignant cancers, 5thed. New York John Wiley.
15. Tsurusaki T, Kanda S, Sakai H, et al (1999). Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis. Br J Cancer, 80, 309.
16. Veikkola T, Alitalo K (1999). VEGFs receptors and angiogenesis. Scmin Cancer Biol, 9, 211.
17. Yamamoto E, Kohama G, Sunakawa H, et al (1983). Mode of invasion, bleomycin sensitivity, and clinical course in squamous cell carcinoma of the oral cavity. Cancer, 51, 2175-80.
18. Yang Y, Ge RM (2002). Expression of VEGF and VEGF-C in laryngeal carcinoma and their clinical significance. J Clin Otorhinolaryngol, 16, 650.
19. Yonemura Y, Fushida S, Bando E, et al (2001). Lymphangiogenesis and the vascular endothelial growth factor receptor (VEGFR)-3 in gastric cancer. Eur J Cancer, 37, 918.
20. Zhongliang W, Yao C, Rueixiang L (2002). Advanced in the researches for vascular endothelial growth factor (VEGF)-C and vascular endothelial growth factor receptor (VEGFR)-3. China J Cancer Prev Treat, 9, 454.